company background image
PIQ

Proteomics International LaboratoriesASX:PIQ Stock Report

Market Cap

AU$100.0m

7D

-6.4%

1Y

88.1%

Updated

25 Sep, 2021

Data

Company Financials
PIQ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PIQ Overview

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics.

Price History & Performance

Summary of all time highs, changes and price drops for Proteomics International Laboratories
Historical stock prices
Current Share PriceAU$0.95
52 Week HighAU$0.48
52 Week LowAU$1.48
Beta1.14
1 Month Change-10.80%
3 Month Change2.70%
1 Year Change88.12%
3 Year Change304.26%
5 Year Change304.26%
Change since IPO322.22%

Recent News & Updates

May 31
We're Not Worried About Proteomics International Laboratories' (ASX:PIQ) Cash Burn

We're Not Worried About Proteomics International Laboratories' (ASX:PIQ) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

PIQAU Life SciencesAU Market
7D-6.4%-5.3%-0.9%
1Y88.1%23.9%24.4%

Return vs Industry: PIQ exceeded the Australian Life Sciences industry which returned 23.9% over the past year.

Return vs Market: PIQ exceeded the Australian Market which returned 24.4% over the past year.

Price Volatility

Is PIQ's price volatile compared to industry and market?
PIQ volatility
PIQ Beta1.14
Industry Beta1.08
Market Beta1

Stable Share Price: PIQ is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: PIQ's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aRichard Lipscombehttps://www.proteomics.com.au

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy.

Proteomics International Laboratories Fundamentals Summary

How do Proteomics International Laboratories's earnings and revenue compare to its market cap?
PIQ fundamental statistics
Market CapAU$99.99m
Earnings (TTM)-AU$2.86m
Revenue (TTM)AU$2.74m

36.6x

P/S Ratio

-35.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PIQ income statement (TTM)
RevenueAU$2.74m
Cost of RevenueAU$813.74k
Gross ProfitAU$1.92m
ExpensesAU$4.78m
Earnings-AU$2.86m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.027
Gross Margin70.26%
Net Profit Margin-104.53%
Debt/Equity Ratio0%

How did PIQ perform over the long term?

See historical performance and comparison

Valuation

Is Proteomics International Laboratories undervalued compared to its fair value and its price relative to the market?

13.14x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PIQ's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PIQ's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PIQ is unprofitable, so we can't compare its PE Ratio to the Global Life Sciences industry average.

PE vs Market: PIQ is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PIQ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PIQ is overvalued based on its PB Ratio (13.1x) compared to the AU Life Sciences industry average (5.2x).


Future Growth

How is Proteomics International Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

40.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Proteomics International Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Proteomics International Laboratories performed over the past 5 years?

-17.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PIQ is currently unprofitable.

Growing Profit Margin: PIQ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PIQ is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.

Accelerating Growth: Unable to compare PIQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PIQ is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (60%).


Return on Equity

High ROE: PIQ has a negative Return on Equity (-37.58%), as it is currently unprofitable.


Financial Health

How is Proteomics International Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: PIQ's short term assets (A$7.3M) exceed its short term liabilities (A$779.0K).

Long Term Liabilities: PIQ's short term assets (A$7.3M) exceed its long term liabilities (A$211.2K).


Debt to Equity History and Analysis

Debt Level: PIQ is debt free.

Reducing Debt: PIQ has no debt compared to 5 years ago when its debt to equity ratio was 55%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PIQ has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PIQ has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 8.8% each year.


Dividend

What is Proteomics International Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PIQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PIQ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PIQ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PIQ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PIQ's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Richard Lipscombe

7.25yrs

Tenure

AU$297,976

Compensation

Dr. Richard John Lipscombe, Ph D (London), MA (Oxford), co-founded Proteomics International Laboratories Limited in 2001 and serves as its Managing Director and Director since June 09, 2014. Mr. Lipscombe...


CEO Compensation Analysis

Compensation vs Market: Richard's total compensation ($USD215.94K) is about average for companies of similar size in the Australian market ($USD284.01K).

Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PIQ's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: PIQ's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.9%.


Top Shareholders

Company Information

Proteomics International Laboratories Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Proteomics International Laboratories Limited
  • Ticker: PIQ
  • Exchange: ASX
  • Founded: 2001
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$99.993m
  • Shares outstanding: 105.26m
  • Website: https://www.proteomics.com.au

Location

  • Proteomics International Laboratories Limited
  • QEII Medical Centre
  • QQ Block
  • Perth
  • Western Australia
  • 6009
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 08:06
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.